Home » Newsletters » BioWorld Science

BioWorld Science

May 4, 2012

View Archived Issues

Ammonia scavenger assessed in healthy volunteers and patients with cirrhosis

Results disclosed from ENABLE trials

Genentech ADC shows potential in prostate cancer models

Novel NCK1/TCR interaction inhibitors designed in Spain

New biologicals with anticancer potential discovered in Belgium

Merck Sharp & Dohme patents novel HER3-specific antibodies

Theravance presents in vivo results on its new SSRI candidate

Novel potential therapies for obesity discovered at Bristol-Myers Squibb

Caisson Biotech forms licensing agreement with Novo Nordisk

FDA approves Levaquin for new indication

Novavax launches phase I trial of A/H5N1 flu vaccine candidate

GenVec obtains NIH grant for respiratory syncytial virus vaccine program

D-Pharm receives first payment from DP-VPA agreement

Transbuccal insulin film produces encouraging first-in-human results

Novel Shp2 inhibitors developed in Germany

NRC discloses new single-domain monoclonal antibodies

Additional patients achieve independence from parenteral support in STEPS 2 study

St. Jude Children's Research Hospital presents new Mdm2/Mdm4 antagonists

Idera Pharmaceuticals reports topline phase II IMO-2055 data

Lead Sunesis product receives European orphan drug status

Omeros unlocks additional class A orphan GPCRs

FDA identifies deficiencies in Adasuve NDA

CSL Behring kicks off study of volume-reduced C1-INH in HAE

FDA extends priority review of crofelemer NDA

Lexicon Pharmaceuticals receives funds to support phase II testing in type 1 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...